The super-regional U.S. property and casualty insurance holding company Heritage Insurance Holdings, Inc. (HRTG) has made significant improvements in its net margin. Its net margin showed an improvement of 3080 basis points over the last two years, which continued into the first quarter of 2025, wherein net margin improved by 320 basis points. Heritage Insurance is prioritizing profitability by ensuring rate adequacy, implementing profit-focused underwriting criteria and limiting new business in saturated o ...

Key Takeaways ZTS gains momentum from flagship drugs like Apoquel, Cytopoint, Simparica Trio and ProHeart 12. Zoetis raised its dividend payout by 16% in 2025, over the previous year. Earnings estimates for 2025 and 2026 continue to rise.Shares of Zoetis (ZTS) have risen 12.5% in a month. The company is a major player in the animal health market. The company operates in seven major product categories, namely, parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical an ...

Key Takeaways HD's Pro segment outpaced DIY in 1Q25, driven by strength in Pro-heavy categories. SRS Distribution boosts HD's Pro credit access, engagement and performance in key markets. HD's Pro upgrades have added more than $1B in annualized sales across 17 high-opportunity markets.The Home Depot Inc. (HD) continues to solidify its leadership in the home improvement market, driven by robust momentum in its Professional (“Pro”) customer segment, even as big-ticket discretionary demand remains soft. In f ...

Key Takeaways INTU shares jumped 22.4% in a month, beating tech sector and software industry benchmarks. Steady revenue growth, effective strategic execution and strong product demand are driving shares. Growing adoption of AI-led tools like Intuit Assist is instilling investors' confidence in INTU's prospects.Intuit (INTU) shares have gained 22.4% over the past month, significantly outperforming the broader Zacks Computer and Technology sector’s return of 9.3% and the Zacks Computer - Software industry’s ...

Key Takeaways Alibaba's diversified growth and AI traction give it the investment edge over Baidu in tech rebound. BABA surged 41.2% year to date, while BIDU gained just 0.9%, showing investor preference. Strong cash position of RMB597.1 billion and ecosystem approach provide Alibaba stability.China's Internet giants have endured a challenging few years marked by regulatory crackdowns, economic headwinds, and intensifying competition. However, as the sector stabilizes and AI emerges as the next growth fro ...

Manfred Stapff's Breakthrough Book Hits #1 on Amazon, Tackles Misinformation with Real-World EvidenceJune 05, 2025 2:00 PM EDT | Source: Avazona Ltd.Summary: Dr. Manfred Stapff's newly released book, Real-World Evidence Unveiled: Navigating the Maze of Modern Misinformation, has soared to #1 on Amazon in multiple categories. New York, New York--(Newsfile Corp. - June 5, 2025) - Candid-Advisory founder and renowned physician-scientist Dr. Manfred Stapff has made a notable impact in the publishi ...

TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Secu ...

Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.Merck & Co Inc's MRK Keytruda (pembrolizumab) is indicated for numerous cancer types.Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Key Takeaways LYRA shares jumped 355.5% this week after LYR-210 met the goal in the phase III ENLIGHTEN 2 CRS study. LYR-210 showed strong symptom relief and improved SNOT-22 scores at 24 weeks, starting as early as week 4. Lyra plans to discuss ENLIGHTEN 2 data with the FDA and may seek approval for LYR-210 in CRS without polyps.Shares of Lyra Therapeutics (LYRA) have skyrocketed 355.5% in a week after the company announced encouraging results from the late-stage study on its lead candidate, LYR-210, whi ...